Involvement of sensitive or challenging body areas is an important treatment consideration since patients with psoriasis in these can have disproportionately greater burden disease. We assess comprehensive clearance by measuring the ability ixekizumab to achieve complete skin (PASI 100) up 5 years when multiple (scalp, nails, palmoplantar [pp] regions) are involved. Data were integrated from UN...
